Neoplasms, Germ Cell and Embryonal Clinical Trial
Official title:
Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors
To evaluate the efficacy of the oxaliplatin-paclitaxel combination i.e. evaluation of tumor response rate using World Health Organization/Union Internationale Contre le Cancer (WHO/UICC) and Indianapolis tumor marker (human chorionic gonadotropin [hCG], alpha fetoprotein [AFP]) criteria in metastatic germ cell cancer patients
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02863003 -
Multicenter Database of Patients With Germ Cell Tumor
|
||
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02533765 -
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
|
Phase 2 | |
| Active, not recruiting |
NCT00393861 -
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
|
Phase 2 | |
| Completed |
NCT02679950 -
Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
|
||
| Completed |
NCT03403777 -
Avelumab in Refractory Testicular Germ Cell Cancer.
|
Phase 2 | |
| Recruiting |
NCT04949282 -
Spanish Series of Patients Treated With the Radionuclide Lutetium177
|
||
| Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04657315 -
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02839694 -
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
|
Phase 1 | |
| Completed |
NCT03012620 -
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
|
Phase 2 | |
| Active, not recruiting |
NCT04222972 -
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
| Enrolling by invitation |
NCT04697446 -
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
|
||
| Terminated |
NCT02859415 -
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
|
Phase 1/Phase 2 | |
| Available |
NCT05592743 -
Vorasidenib Expanded Access Program
|